Melanotan II: difference between revisions
Diff·revision 2 → 3·12:22, 1 Dec 2024
Difference between revision 2 and revision 3 of Melanotan II. 6 lines changed; the page grew by 793 bytes.
| Revision 2 — 13:09, 22 Nov 2024 Hedgerow_Hal (talk) split overlong sentence 1,177 bytes ±0 | Revision 3 — 12:22, 1 Dec 2024 ShortDescShai (talk) split the pharmacology section from the marketing history 1,970 bytes +793 | ||
|---|---|---|---|
| 11 | Non-selectivity is the defining property. Agonism at MC1R produces melanogenesis, the effect for which it is sought; agonism at MC4R affects appetite and sexual function; agonism at MC3R and MC5R contributes further effects. A single compound producing all of them simultaneously is a pharmacological blunt instrument.{{r|hadley2005}} | 11 | Non-selectivity is the defining property. Agonism at MC1R produces melanogenesis, the effect for which it is sought; agonism at MC4R affects appetite and sexual function; agonism at MC3R and MC5R contributes further effects. A single compound producing all of them simultaneously is a pharmacological blunt instrument.{{r|hadley2005}} |
| 12 | 12 | ||
| + | 13 | == Pharmacology == | |
| + | 14 | The melanocortin system comprises five receptors with distinct distributions. MC1R on melanocytes controls the switch between pheomelanin and eumelanin synthesis; MC4R in the hypothalamus is central to appetite regulation and is the target of approved anti-obesity compounds in rare genetic conditions. See [[Arcuate nucleus]].{{r|cone2005}} | |
| + | 15 | ||
| + | 16 | Melanotan II activates all of these. Selective compounds developed subsequently — [[Bremelanotide|bremelanotide]] for sexual dysfunction, and MC4R-directed agents for genetic obesity — represent the pharmacological correction of that non-selectivity.{{r|hadley2005}} | |
| + | 17 | ||
| 13 | == References == | 18 | == References == |
| 14 | {{reflist}} | 19 | {{reflist}} |
| 15 | <ref name="hadley2005">Hadley ME, Dorr RT. "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization." ''Peptides'' 26(10):1687–1689 (2005). PMID 16112778.</ref> | 20 | <ref name="hadley2005">Hadley ME, Dorr RT. "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization." ''Peptides'' 26(10):1687–1689 (2005). PMID 16112778.</ref> |
| + | 21 | <ref name="cone2005">Cone RD. "Anatomy and regulation of the central melanocortin system." ''Nature Neuroscience'' 8(5):571–578 (2005). PMID 15856065.</ref> | |
| 16 | 22 | ||
| 17 | {{DEFAULTSORT:Melanotan II}} | 23 | {{DEFAULTSORT:Melanotan II}} |